Mertect lsp en es it fr

Mertect lsp Brand names, Mertect lsp Analogs

Mertect lsp Brand Names Mixture

  • No information avaliable

Mertect lsp Chemical_Formula


Mertect lsp RX_link

Mertect lsp fda sheet

Mertect lsp msds (material safety sheet)

Mertect lsp Synthesis Reference

No information avaliable

Mertect lsp Molecular Weight

192.258 g/mol

Mertect lsp Melting Point

246-266 oC

Mertect lsp H2O Solubility

1.07E+004 mg/L

Mertect lsp State


Mertect lsp LogP


Mertect lsp Dosage Forms

400 mg and 600 mg tablets for oral administration

Mertect lsp Indication

For the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening.

Mertect lsp Pharmacology

Tocainide is a primary amine analog of lidocaine with antiarrhythmic properties useful in the treatment of ventricular arrhythmias. Tocainide, like lidocaine, produces dose dependent decreases in sodium and potassium conductance, thereby decreasing the excitability of myocardial cells. In experimental animal models, the dose-related depression of sodium current is more pronounced in ischemic tissue than in normal tissue. Tocainide is a Class I antiarrhythmic compound with electrophysiologic properties in man similar to those of lidocaine, but dissimilar from quinidine, procainamide, and disopyramide.

Mertect lsp Absorption

Following oral administration, the bioavailability approaches 100 percent, and is unaffected by food.

Mertect lsp side effects and Toxicity

The oral LD50 of tocainide was calculated to be about 800 mg/kg in mice, 1000 mg/kg in rats, and 230 mg/kg in guinea pigs; deaths were usually preceded by convulsions.

Mertect lsp Patient Information

Mertect lsp Organisms Affected

Humans and other mammals